Enfuvirtide: A new class of antiretroviral therapy for HIV infection

Oral Diseases

Volumn 10, Issue 6, 2004, Pages 327-329

  Leao, J C ^a,b   Frezzini, C ^b   Porter, S ^b  

^a FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

ART; Enfuvirtide; Entry inhibitor; HIV therapy; Side effects

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; ENFUVIRTIDE; INDINAVIR; LAMIVUDINE; NELFINAVIR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DIZZINESS; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG COST; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG POTENTIATION; DRUG TOLERABILITY; DYSGEUSIA; EDEMA; FATIGUE; HEALTH CARE COST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; INFECTION CONTROL; INJECTION SITE; LIP DISEASE; NAUSEA; NEUROPATHY; PRIORITY JOURNAL; QUALITY OF LIFE; SELF INJECTION; SIDE EFFECT; SKIN MANIFESTATION; TREATMENT FAILURE;

CD4-POSITIVE T-LYMPHOCYTES; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV INFECTIONS; HUMANS; INFUSIONS, PARENTERAL; PEPTIDE FRAGMENTS;

EID: 9444292849     PISSN: 1354523X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1601-0825.2004.01042.x     Document Type: Article

References (29)

1. Ball RA, Kinchelow T (2003). Injection site reactions with the HIV-1 fusion inhibitor enfuvirtide. J Am Acad Dermatol 49: 826-831.
2. Barretina J, Blanco J, Armand-Ugon M et al (2003). Anti-HIV-1 activity of enfuvirtide (T-20) by inhibition of bystander cell death. Antivir Ther 8: 155-161.
3. Behrens GM, Meyer-Olson D, Stoll M et al (2003). Clinical impact of HIV-related lipodystrophy and metabolic abnormalities on cardiovascular disease. AIDS 17 Suppl 1: S149-S154.
4. Celano SA (2003). Enfuvirtide access, administration, and patient education. Hopkins HIV Rep 15: 1-12.
5. Cohen CJ, Dusek A, Green J et al (2002). Long-term treatment with subcutaneous T-20, a fusion inhibitor, in HIV-infected patients: patient satisfaction and impact on activities of daily living. AIDS Patient Care STDS 16: 327-335.
6. Cole SR, Hernan MA, Robins JM et al (2003). Effect of highly active antiretroviral therapy on time to acquired immunodeficiency syndrome or death using marginal structural models. Am J Epidemiol 158: 687-694.
7. Derdeyn CA, Decker JM, Sfakianos JN et al (2000). Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J Virol 74: 8358-8367.
8. European Commission (2003). European Commission approves Fuzeon following FDA approval - first HIV-fusion inhibitor in fight against HIV. Infection 31: 7-8.
9. Faucher JF, Challier B, Chirouze C et al (2004). Predictive factors of virological response to primary antiretroviral treatment. Presse Med 33: 310-315.
10. Gazzaruso C, Bruno R, Garzaniti A et al (2003). Hypertension among HIV patients: prevalence and relationships to insulin resistance and metabolic syndrome. J Hypertens 21: 1377-1382.
11. Giles C (2001). T-20 phase III studies underway. Surviv News (Atlanta Ga) 12: 1-12.
12. Hardy H, Skolnik PR (2004). Enfuvirtide, a new fusion inhibitor for therapy of human immunodeficiency virus infection. Pharmacotherapy 24: 198-211.
13. Kilby JM, Eron JJ (2003). Novel therapies based on mechanisms of HIV-1 cell entry. N Engl J Med 348: 2228-2238.
14. Lalezari JP, DeJesus E, Northfelt DW et al (2003a). A controlled phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults. Antivir Ther 8: 279-287.
15. Lalezari JP, Eron JJ, Carlson M et al (2003b). A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy. AIDS 17: 691-698.
16. Lalezari JP, Patel IH, Zhang X et al (2003e). Influence of subcutaneous injection site on the steady-state pharmacokinetics of enfuvirtide (T-20) in HIV-1-infected patients. J Clin Virol 28: 217-222.
17. Laurence J (2002). T-20: a model for novel anti-HIV drugs in development. AIDS Read 12: 469-470.
18. Lazzarin A, Clotet B, Cooper D et al (2003). Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 348: 2186-2195.
19. Locatelli GA, Campiani G, Cancio R et al (2004). Effects of drug resistance mutations L100I and V106A on the binding of pyrrolobenzoxazepinone nonnucleoside inhibitors to the human immunodeficiency virus type 1 reverse transcriptase catalytic complex. Antimicrob Agents Chemother 48: 1570-1580.
20. Maggi P, Ladisa N, Cinori E et al (2004). Cutaneous injection site reactions to long-term therapy with enfuvirtide. J Antimicrob Chemother.
21. Mocroft A, Ledergerber B, Katlama C et al (2003). Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 362: 22-29.
22. Mooser V (2003). Atherosclerosis and HIV in the highly active antiretroviral therapy era: towards an epidemic of cardiovascular disease? AIDS 17(Suppl. 1): S65-S69.
23. Perez-Elias MJ, Moreno A, Moreno S et al (2003). Differences in durability of treatment with initial PI-based regimens. HIV Clin Trials 4: 391-399.
24. Reeves JD, Gallo SA, Ahmad N et al (2002). Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics. Proc Natl Acad Sci USA 99: 16249-16254.
25. Robertson D (2003). US FDA approves new class of HIV therapeutics. Nat Biotechnol 21: 470-471.
26. Roman F, Gonzalez D, Lambert C et al (2003). Uncommon mutations at residue positions critical for enfuvirtide (T-20) resistance in enfuvirtide-naive patients infected with subtype B and non-B HIV-1 strains. J Acquir Immune Defic Syndr 33: 134-139.
27. Rummelein N, Jager H (2003). Entry-inhibitors. MMW Fortschr Med 145: 16-20.
28. Verhofstede C, Noe A, Demecheleer E et al (2004). Drug-resistant variants that evolve during nonsuppressive therapy persist in HIV-1-infected peripheral blood mononuclear cells after long-term highly active antiretroviral therapy. J Acquir Immune Defic Syndr 35: 473-483.
29. Wei X, Decker JM, Liu H et al (2002). Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 46: 1896-1905.